Sacubitril-Valsartan for Hemodialysis Patients
What You Need to Know Before You Apply
What is the purpose of this trial?
This randomized placebo-controlled clinical trial will evaluate the effect of sacubitril/valsartan (compared with placebo) on echocardiographic measures of hypervolemia, preservation of residual renal function, and key safety parameters in incident hemodialysis patients.
Will I have to stop taking my current medications?
The trial requires that you have not taken an ACE inhibitor for 36 hours before joining. If you are currently using sacubitril/valsartan, you must stop at least 30 days before participating. Other medications are not specifically mentioned, so it's best to discuss with the trial team.
Is sacubitril-valsartan safe for humans?
Sacubitril-valsartan (Entresto) is generally safe for humans but can cause side effects like low blood pressure, swelling (angioedema), kidney problems, high potassium levels, low sodium levels, and in rare cases, liver injury. It should not be used during pregnancy, breastfeeding, or with certain other medications in people with diabetes.12345
How is the drug sacubitril-valsartan unique for hemodialysis patients?
Sacubitril-valsartan is unique because it combines two components that work together to improve heart function and reduce blood pressure in hemodialysis patients, showing better results than using valsartan alone. It has been shown to improve heart function and reduce symptoms in patients with heart failure and hypertension undergoing dialysis, without causing common side effects like high potassium levels.25678
What data supports the effectiveness of the drug sacubitril-valsartan for hemodialysis patients?
Who Is on the Research Team?
Finnian Mc Causland, MBBCh, MMSc
Principal Investigator
Brigham and Women's Hospital
Are You a Good Fit for This Trial?
Adults over 18 who recently started hemodialysis can join this trial. They must have stable blood pressure, not be on certain heart medications, and able to consent. Excluded are those with recent major heart issues, planned transplants, severe liver disease, untreated serious arrhythmias or cancer within the last year.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive sacubitril/valsartan or placebo, with dose titration over the first 4 weeks and maintenance for 12 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Placebo
- Sacubitril-valsartan
Sacubitril-valsartan is already approved in European Union, United States for the following indications:
- Heart failure with reduced ejection fraction
- Chronic heart failure with reduced ejection fraction
Find a Clinic Near You
Who Is Running the Clinical Trial?
Brigham and Women's Hospital
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator